Imperial College London
Portrait Picture

Dr Nick Powell

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Gastroenterology
 
 
 
//

Contact

 

nicholas.powell

 
 
//

Assistant

 

Mrs Heather Bones +44 (0)20 7594 2429

 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Moulton:2019:10.1111/cei.13276,
author = {Moulton, CD and Pavlidis, P and Norton, C and Norton, S and Pariante, C and Hayee, B and Powell, N},
doi = {10.1111/cei.13276},
journal = {Clinical and Experimental Immunology},
pages = {308--318},
title = {Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation?},
url = {http://dx.doi.org/10.1111/cei.13276},
volume = {197},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Depressive symptoms are reported by more than 20% of people with inflammatory bowel disease (IBD), while sleep difficulties and fatigue are even more common. Co-morbid depressive symptoms predict a poor IBD course, including increased risk of relapse and surgery, which is inconsistently improved by psychological treatments. Rather than being distinct systems, there is compelling evidence for bidirectional communication between gut and brain, driven by neural, metabolic, endocrine and inflammatory mediators. An emerging concept is that depressive symptoms may be mechanistically linked to excess inflammation and dysregulation of the gut-brain axis. Given the close link between the intestinal microbiota and host immune responses, patients prone to shifts in their intestinal microbiome, including smokers, those with poor diet and early life stress, may be exposed to exaggerated immune responses. Excess inflammation is associated with brain changes (depressive symptoms, fatigue, sleep difficulties) and worsening gastrointestinal symptoms, which are exacerbated by psychological distress. Equally, treatments both for depressive symptoms and IBD provide opportunities to break this cycle by reducing the causes and effects of inflammation. As well as addressing potential risk factors such as smoking and diet, treatments to alter the microbiome may reduce depressive symptoms. Observational evidence suggests that anti-inflammatory treatments for IBD may improve co-morbid depressive symptoms correlating with reduction in inflammation. With a growing range of treatments targeting inflammation centrally, peripherally and in the gut, IBD provides a unique model to understand the interplay between brain and gut in the pathogenesis of depressive symptoms, both in IBD and in the whole population.
AU  - Moulton,CD
AU  - Pavlidis,P
AU  - Norton,C
AU  - Norton,S
AU  - Pariante,C
AU  - Hayee,B
AU  - Powell,N
DO  - 10.1111/cei.13276
EP  - 318
PY  - 2019///
SN  - 0009-9104
SP  - 308
TI  - Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation?
T2  - Clinical and Experimental Immunology
UR  - http://dx.doi.org/10.1111/cei.13276
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30762873
UR  - http://hdl.handle.net/10044/1/75969
VL  - 197
ER  -
Download